Biotech

All Articles

BMS trenches TIGIT, ignoring $200M bank on Agenus bispecific

.Bristol Myers Squibb is axing one more big wager from the Caforio age, ending an offer for Agenus' ...

Nuvation stops BET inhibitor after thinking about phase 1 data

.After having a look at stage 1 record, Nuvation Biography has actually determined to halt work on i...

' Medical instinct' led FDA consultants to back Zevra's unusual condition med

.Zevra Therapeutics' rare ailment medication appears to become on the road to confirmation this loss...

Pfizer takes $230M reached after axing failed DMD genetics treatment

.Pfizer's period 3 Duchenne muscle dystrophy (DMD) gene treatment failure has blown a $230 million o...

AC Immune observes 'site' potential in Alzheimer's medicine data

.After greater than two decades of focus on neurodegenerative ailments, Swiss biotech hvac Immune sy...

GSK falls ph. 2 HPV vaccination over absence of best-in-class prospective

.GSK has scrapped a stage 2 individual papillomavirus (HPV) vaccine from its own pipeline after choo...

OS Treatments refiles $6M IPO to money HER2 drug, preclinical ADCs

.OS Therapies are going to specify on the NYSE American sell swap today using a $6.4 thousand IPO th...

ALX's waning CD47 feedback price sends out inventory spiraling down

.ALX Oncology's period 2 gastric cancer cells feedback price has compromised. After viewing its own ...

Ionis centers eye illness coming from intendeds of Roche-partnered prospect after records let down

.Yet Another of Ionis Pharmaceuticals' vital midphase readouts has disappointed assumptions, trigger...

Biogen's chief executive officer said no unsafe handle 2023. He's ready to be bold

.While Biogen's pharma peers are actually looking for late-stage possessions along with little threa...